Exosome Diagnostics
Latest round
- Series C
Last raised
- Jul 2017
Total raised
- $95M
Investors
- 9
About Exosome Diagnostics
Exosome Diagnostics, Inc.Founded in 2008 and headquartered in Waltham, US, Exosome Diagnostics, Inc. develops diagnostic solutions focused on prostate cancer detection.Exosome Diagnostics, Inc. specializes in advanced diagnostic solutions for prostate cancer, primarily through its flagship product, the ExoDx Prostate Test. This exosome-based liquid biopsy test is designed to provide a non-invasive method for assessing prostate cancer risk, specifically targeting patients with Prostate-Specific Antigen (PSA) levels in the 'gray zone' of 2–10 ng/mL. The test assists in guiding biopsy decisions by distinguishing between high-grade and low-grade prostate cancer as well as benign conditions, facilitating earlier disease detection. The ExoDx Prostate Test is recognized in clinical guidelines from the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA), reinforcing its clinical relevance. Exosome Diagnostics serves a diverse range of clients, including healthcare providers, urologists, and institutions, primarily within the United States.Exosome Diagnostics operates on a revenue model centered around its proprietary ExoDx Prostate Test and related services. The company engages in business-to-business transactions with healthcare providers and institutions, directly offering its tests to clinicians who utilize them in patient evaluations. Revenue is generated through the sale of the ExoDx Prostate Test, which involves a straightforward transaction structure where healthcare providers order the test for their patients. The firm provides an at-home collection kit to facilitate sample collection, enhancing accessibility for patients and increasing test uptake.Exosome Diagnostics, Inc.29 mn secured on July 5, 2017. The company plans to develop new diagnostic tests targeted at additional cancer types and enhance its existing pipeline. Furthermore, Exosome Diagnostics is exploring expansion into international markets, with a focus on Europe and Asia by 2025.
Who invested in Exosome Diagnostics
9 investors across 4 rounds
See all investors in Exosome Diagnostics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Exosome Diagnostics
Who invested in Exosome Diagnostics?
Exosome Diagnostics has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Exosome Diagnostics raised?
Exosome Diagnostics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Exosome Diagnostics last raise money?
Exosome Diagnostics's most recent round on record is a Series C, in Jul 2017.
What does Exosome Diagnostics do?
Exosome Diagnostics is a biotechnology company.
Where is Exosome Diagnostics headquartered?
Exosome Diagnostics is headquartered in Waltham, US.
Which VCs invest in companies like Exosome Diagnostics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Exosome Diagnostics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Exosome Diagnostics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.